Phenergan (Promethazine) Should Generally Be Avoided in a 69-Year-Old Female
Promethazine is generally not safe for a 69-year-old female and should be avoided due to its strong anticholinergic properties, which significantly increase risks of cognitive impairment, falls, delirium, and other serious adverse effects in older adults.
Why Promethazine is Problematic in Older Adults
The 2021 Mayo Clinic polypharmacy guidelines explicitly identify strongly anticholinergic medications like promethazine as high-risk drugs that should be deprescribed in older adults 1. The 2015 American Geriatrics Society guidelines specifically list promethazine among medications to avoid postoperatively in older adults to prevent delirium 2.
Key Safety Concerns
Anticholinergic Burden:
- Promethazine has strong anticholinergic effects that are poorly tolerated in aged patients 1
- These effects cause negative impacts on vision, urination, constipation, and cognition 1
- The "anticholinergic burden" from such medications is associated with decline in cognition, functional status, and activities of daily living scores 1
- Acetylcholine physiology naturally declines with aging and is further blocked by anticholinergics 1
Serious Adverse Effects: The adverse effects profile is particularly concerning in older adults 3, 4, 3:
- Hypotension
- Respiratory depression
- Neuroleptic malignant syndrome
- Extrapyramidal effects (restlessness to oculogyric crises)
- Confusion (documented in studies of older patients) 3
Increased Atrial Fibrillation Risk: A 2020 study found that promethazine users aged ≥65 had a 58% increased risk of hospitalization for atrial fibrillation compared to loratadine users (OR 1.58; 95% CI 1.07-2.63), with even higher risk compared to betahistine 5. The risk was particularly elevated in patients with prior cardiac arrhythmia.
Severe Tissue Injury Risk: The FDA drug label carries warnings about severe chemical irritation and tissue damage, including gangrene, regardless of route of administration 6. Injectable promethazine has an FDA black box warning since 2009 for risk of serious tissue injury 7. The Institute for Safe Medication Practices and American Society of Health-System Pharmacists have advocated for removing all injectable promethazine from healthcare settings 8.
Clinical Context Matters
While the sedation literature 3, 4, 3, 4 describes promethazine use during endoscopic procedures, this represents a controlled, monitored setting that differs fundamentally from general outpatient or inpatient use in a 69-year-old woman. Even in these controlled settings, adverse effects including hypotension, confusion, and respiratory depression were documented 3.
The Evidence on Lower Doses
Two studies examined lower doses in elderly patients:
- A 2010 study found 6.25 mg IV promethazine as effective as higher doses with fewer adverse drug reactions in hospitalized elderly 9
- A 2006 study showed low-dose promethazine (6.25-12.5 mg) relieved nausea as effectively as ondansetron 4 mg 10
However, even at lower doses, the fundamental anticholinergic properties remain problematic for the reasons outlined in the geriatric guidelines 1, 2.
Safer Alternatives
For nausea/vomiting:
- Ondansetron is the preferred alternative with a favorable safety profile, no anticholinergic effects, and no FDA black box warning 7, 8
- Multiple studies demonstrate ondansetron's efficacy and safety in older adults 7, 10
For sedation/sleep:
- The 2025 BJPsych bulletin explicitly states promethazine is not suitable as a sleep aid, particularly for mental health patients, recommending cognitive-behavioral therapy for insomnia as NICE's first-line recommendation 11
For allergic conditions:
- Non-sedating antihistamines like loratadine are safer alternatives 5
Common Pitfalls to Avoid
Don't assume "it's just an antihistamine" - Promethazine is a phenothiazine with multiple mechanisms of action and significant risks 3, 4
Don't rely on historical use patterns - Just because promethazine has been used for decades doesn't make it appropriate for older adults given current evidence 1, 2
Don't ignore the cumulative anticholinergic burden - If this patient is on other medications with anticholinergic properties, adding promethazine compounds the risk 1
Don't use for sleep - There are evidence-based alternatives with better safety profiles 11
Bottom Line
The convergence of high-quality geriatric guidelines 1, 2, FDA warnings 6, professional society recommendations 8, and research evidence 5 makes a compelling case against promethazine use in a 69-year-old female. The risks of cognitive decline, falls, delirium, cardiac arrhythmias, and tissue injury outweigh potential benefits when safer, equally effective alternatives exist.